Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants With DEE Followed by an Open-Label Extension

NCT07010471 is registered in ClinicalTrials.gov with Praxis Precision Medicines as lead sponsor.

NCT NCT07010471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07010471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants With DEE Followed by an Open-Label Extension
Lead sponsor
Praxis Precision Medicines
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 9, 2025
Completion date
November 30, 2027
Enrollment
160 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

developmental and epileptic encephalopathy 1